Options
Dra. Gerli-Candia, Lorena
Nombre de publicación
Dra. Gerli-Candia, Lorena
Nombre completo
Gerli Candia, Lorena Andrea
Facultad
Email
loregerli@ucsc.cl
ORCID
Scopus Author ID
6506865225
Researcher ID
GLU-4473-2022
2 results
Research Outputs
Now showing 1 - 2 of 2
- PublicationA computational study of the antioxidant power of eugenol compared to Vitamin C(QuÃmica Nova, 2023)
;Rasul, Hezha ;Aziz, Bakhtyar ;Salgado-Morán, Guillermo ;Mendoza-Huizar, Luis ;Belhassan, Assia; ;Cardona-Villada, WilsonSadasivam, KandasamyThe antioxidant power of eugenol and vitamin C was examined by analyzing the ability of these ligands to bind to the NADPH oxidase protein target and evaluating their bond interactions with critical residues. The results confirm that docked ligands are more stable in the specified active region of 2CDU during a MD simulation of 100 ns and 2CDU protein-ligand interactions with docked ligands showed significant hydrogen bond, hydrophobic, and water bridge formation. Eugenol exhibits hydrogen bond interactions with critical residues in the selective pocket in comparison to vitamin C. Also, eugenol had a similar binding orientation and very considerable stability in the selective pocket of 2CDU with a high binding energy with lipophilic energy. The electrostatic potential maps indicate that for eugenol, the –OH and –OCH3 sites, while that the –OH and –CO functional groups in vitamin C are responsible of the antioxidant activities of these compounds. HAT and SET mechanisms suggest that eugenol may become a better antioxidant than vitamin C. - PublicationSearching possible SARS-CoV-2 main protease inhibitors in constituents from herbal medicines using in silico studies(Taylor & Francis, 2023)
; ;Rasul, Hezha ;Vinay-Thomas, Noel ;Ghafour, Dlzar ;Aziz, Bakhtyar ;Salgado, GuillermoMendoza-Huizar, L.The largest threat to civilization since the Second World War is the spread of the new coronavirus disease (COVID-19). Therefore, there is an urgent need for innovative therapeutic medicines to treat COVID-19. Reusing bio-actives is a workable and efficient strategy in the battle against new epidemics because the process of developing new drugs is time-consuming. This research aimed to identify which herbal remedies had the highest affinity for the receptor and assess a variety of them for potential targets to suppress the SARS-CoV-2 Mpro. The use of AutoDock Vina for structure-based virtual screening was done first due to the importance of protein interactions in the development of drugs. Molecular docking was used in the comparative study to assess 89 different chemicals from medicinal herbs. To anticipate their effectiveness against the primary protease of SARS-CoV-2, more analysis was done on the ADMET profile, drug-likeness, and Lipinski’s rule of five. The next step involved three replicas of 100 ns-long molecular dynamics simulations on the potential candidates, which were preceded by calculations of the binding free energy of MM-GBSA. The outcomes showed that Achyrodimer A, Cinchonain Ib, Symphonone F, and Lupeol acetate all performed well and had the highest 6LU7 binding affinities. Using RMSD, RMSF, and protein-ligand interactions, the stability of the protein-ligand complex was assessed. The studies indicate that bioactive substances obtained from herbal medicines may function as a COVID-19 therapeutic agent, necessitating additional wet lab research to confirm their therapeutic potential, efficacy, and pharmacological capacity against the condition.